[1]. Ubiquitin-like 3 as a new protein-sorting factor for small extracellular vesicles.
Cell structure and function [巻]47 [号]1 [頁]1 -18 （2022年）
[DOI] [2]. 乳癌患者の妊娠・出産と生殖医療に関する診療ガイドライン改訂のポイント(乳癌関連)
日本がん・生殖医療学会誌 (一社)日本がん・生殖医療学会 [巻]5 [号]1 [頁]16 -22 （2022年）
[3]. A difficult-to-diagnose fibromatosis-like metaplastic carcinoma of the breast: a case report
Surg Case Rep . [巻]7 [号]1 [頁]16 （2021年） [査読] 有
[4]. Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD)
Trials [巻]21 [号]1 [頁]391391 （2020年） [査読] 有
[5]. The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition.
Breast cancer (Tokyo, Japan) （2020年） [査読] 有
[DOI]